Sanofi, GSK initiate phase III trial of COVID-19 vaccine

By The Science Advisory Board staff writers

May 28, 2021 -- Sanofi and GlaxoSmithKline started their phase III trial to assess the safety, efficacy, and immunogenicity of their recombinant-protein COVID-19 vaccine candidate.

The trial will evaluate how the vaccine targets the original variant, the B.1.351 variant, and other circulating variants.

The enrollment follows positive results from the phase II trial, which showed the vaccine produced strong rates of neutralizing antibody responses in all adult age groups. Pending positive phase III outcomes and regulatory reviews, the vaccine may be approved by the last quarter of 2021.

Copyright © 2021
To access all The ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
I have read and agree to the privacy policy and terms of service and wish to opt-in for

Already have an account? Sign in here